Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals
(NQ:
IONS
)
52.78
USD
+1.51 (+2.95%)
Official Closing Price
Updated: 4:29 PM EST, Mar 5, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Ionis Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
March 01, 2021
The Janice Wiesman Young Investigator Grant Program honors leading expert on neurological impact of amyloidosis
From
PR Newswire
Ionis Pharmaceuticals is Now Oversold (IONS)
February 26, 2021
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...
Tags
Stocks
From
Market News Video
Ionis Pharmaceuticals, Inc. (IONS) Q4 2020 Earnings Call Transcript
February 24, 2021
IONS earnings call for the period ending December 31, 2020.
Tags
Market News
IONS
From
Motley Fool
The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
February 24, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Tags
MMSI
Offerings
SAGE
From
Benzinga
Ionis Pharmaceuticals: Q4 Earnings Insights
February 24, 2021
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) remained unaffected after the company reported Q4 results. Quarterly ...
Tags
BZI/Recaps
News
IONS
From
Benzinga
Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
February 24, 2021
Achieved 2020 financial guidance
From
PR Newswire
The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings
February 20, 2021
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before ...
Tags
NTRA
PBYI
NVS
From
Benzinga
Ionis to present at upcoming investor conferences
February 19, 2021
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that management will participate in a virtual fireside chat at the following investor conferences:
From
PR Newswire
Ionis to hold 2020 financial results webcast
February 11, 2021
Webcast scheduled for Wednesday, February 24 at 9:00 a.m. Eastern Time
From
PR Newswire
Ionis Pharmaceuticals Larger Than S&P 500 Component Robert Half International
February 09, 2021
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ionis Pharmaceuticals Inc (IONS) was identified as having a larger market cap than the smaller end of the...
Tags
Stocks
From
Market News Video
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
February 02, 2021
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the ...
Tags
GILD
HEXO
ABBV
From
Benzinga
The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement
January 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Tags
IMMP
HOLX
CASI
From
Benzinga
Stocks That Hit 52-Week Highs On Tuesday
January 26, 2021
This morning 163 companies set new 52-week highs. Areas of Significance: The largest company by market cap ...
Tags
RNET
LAND
OPRX
From
Benzinga
The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market
January 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Tags
Market News
RNLX
CCXI
From
Benzinga
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
January 08, 2021
From
GlobeNewswire News Releases
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
January 07, 2021
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief clinical development officer. In this role, Dr. Schneider...
From
PR Newswire
Notable ETF Outflow Detected - XBI, AGIO, SAGE, IONS
January 05, 2021
Symbols mentioned in this story: XBI, AGIO, SAGE, IONS Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These...
Tags
ETFs
From
ETF Channel
Ionis to present at 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the virtual...
From
PR Newswire
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
December 28, 2020
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the ...
Tags
CVS
CALA
General
From
Benzinga
Notable ETF Inflow Detected - XBI, EDIT, TGTX, IONS
December 28, 2020
Symbols mentioned in this story: XBI, EDIT, TGTX, IONS Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These...
Tags
ETFs
From
ETF Channel
Ionis Pharmaceuticals (IONS) Shares Cross Above 200 DMA
December 18, 2020
In trading on Friday, shares of Ionis Pharmaceuticals Inc (IONS) crossed above their 200 day moving average of $52.90, changing hands as high as $54.57 per share. Ionis Pharmaceuticals Inc shares are...
Tags
Stocks
From
Market News Video
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
December 17, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that its founder and executive chairman Stanley T. Crooke, M.D., Ph.D., will retire from Ionis and...
From
PR Newswire
Ionis highlights achievements, commercial strategy and technology advancements at Investor Day
December 08, 2020
- Prioritizing and preparing its growing Ionis-owned pipeline for commercialization
From
PR Newswire
Red Clover Market Size, Share, Price, Trends, Growth, Analysis, Key Players, Outlook, Report, Forecast 2020-2025 | ExpertMarketResearch.com
December 04, 2020
Tags
iCN Internal Distribution
Reportedtimes
Research Newswire
From
iCrowdNewswire
Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference
December 02, 2020
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtual fireside chat at the BMO 2020 Growth and ESG Conference...
From
PR Newswire
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
December 01, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients with familial chylomicronemia syndrome (FCS). FCS is a...
From
PR Newswire
Ionis to hold virtual investor day event
December 01, 2020
Webcast scheduled for Monday, December 7 at 11:00 a.m. Eastern Time
From
PR Newswire
Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
November 30, 2020
Phase 1 results for ION449 (AZD8233) demonstrate best-in-class potential, showing potent, dose-dependent PCSK9 reductions of >90% with favorable safety profile
From
PR Newswire
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
November 23, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential...
From
PR Newswire
First Week of IONS July 2021 Options Trading
November 23, 2020
Investors in Ionis Pharmaceuticals Inc (IONS) saw new options begin trading this week, for the July 2021 expiration. One of the key data points that goes into the price an option buyer is willing to...
Tags
Stocks
From
Market News Video
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.